Last reviewed · How we verify
Anti-IL8
Anti-IL8 binds to interleukin-8 (IL-8), a chemokine involved in inflammation, to reduce its activity.
Anti-IL8 binds to interleukin-8 (IL-8), a chemokine involved in inflammation, to reduce its activity. Used for Moderate to severe chronic plaque psoriasis, Rheumatoid arthritis.
At a glance
| Generic name | Anti-IL8 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | monoclonal antibody |
| Target | IL-8 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By binding to IL-8, Anti-IL8 prevents it from interacting with its receptors, thereby inhibiting the recruitment of neutrophils and other inflammatory cells, which can help in reducing inflammation and associated symptoms.
Approved indications
- Moderate to severe chronic plaque psoriasis
- Rheumatoid arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
Key clinical trials
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (PHASE2)
- Identify a Specific Immune Profile in Patients With Chronic Pelvic Pain Resistant to First-line Treatments by Measuring Th1, Th2, Th17, and Treg Cytokines Produced After Non-specific Functional Cell Stimulation - ImmunoCPP (NA)
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (PHASE2)
- Immune Response During the Conservative and Minimal Invasive Treatment of Pain Caused by Lumbar Disc Herniation (NA)
- Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma (PHASE1)
- Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 (PHASE2)
- Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) (PHASE1, PHASE2)
- Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-IL8 CI brief — competitive landscape report
- Anti-IL8 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI